Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 2Terminated 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Ovarian Neoplasms 23Breast Neoplasms 11Fallopian Tube Neoplasms 10Multiple Myeloma 7Carcinoma, Ovarian Epithelial 6Neoplasms 5Neoplasms, Plasma Cell 3Lymphoma 3Recurrence 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Lymphoma, Non-Hodgkin 2Carcinoma 2Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumors 1Small Cell Lung Carcinoma 1Sarcoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Patient Participation 1Ovarian Diseases 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Mesothelioma, Malignant 1Melanoma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell 1Lymphoma, Primary Effusion 1Liver Neoplasms 1

Interventions

Lenalidomide 5Rituximab 4Brentuximab Vedotin 4Vincristine 3Etoposide 3Cyclophosphamide 3romidepsin 2Vorinostat 2Granulocyte Colony-Stimulating Factor 2Gemcitabine 2Doxorubicin 2Dasatinib 2tislelizumab 1selinexor 1plerixafor 1pembrolizumab 1pegfilgrastim 1parsaclisib 1obinutuzumab 1obatoclax 1monomethyl auristatin E 1liposomal doxorubicin 1ixazomib 1idelalisib 1ibrutinib 1gemcitabine-oxaliplatin regimen 1fludarabine 1etoposide phosphate 1denileukin diftitox 1copanlisib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Lymphoma, T-Cell, Peripheral × liposomal doxorubicin × Clear all
NCT00632827 2020-04-27

Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak)

University of California, San Francisco

Phase 2 Terminated
21 enrolled 13 charts
Lymphoid

Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡